Functional cure for chronic hepatitis B: accessibility, durability, and prognosis

Hepatitis B surface antigen (HBsAg) clearance is regarded as the ideal endpoint for antiviral treatment in terms of drug withdrawal safety and improvements in prognosis. However, the overall rate of HBsAg clearance is low and differs based on treatment method and course. The recent application of co...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Aixin, Lin, Xiao, Chen, Xinyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176700/
https://www.ncbi.nlm.nih.gov/pubmed/34082765
http://dx.doi.org/10.1186/s12985-021-01589-x
_version_ 1783703299767140352
author Song, Aixin
Lin, Xiao
Chen, Xinyue
author_facet Song, Aixin
Lin, Xiao
Chen, Xinyue
author_sort Song, Aixin
collection PubMed
description Hepatitis B surface antigen (HBsAg) clearance is regarded as the ideal endpoint for antiviral treatment in terms of drug withdrawal safety and improvements in prognosis. However, the overall rate of HBsAg clearance is low and differs based on treatment method and course. The recent application of combined and extended treatment strategies have improved the HBsAg clearance rate, and several patients achieved HBsAg clearance in clinical treatment. In addition, the durability of and clinical outcomes after HBsAg clearance have become the focus of both researchers and clinicians. This article reviews HBsAg clearance in terms of accessibility, durability, improvements in prognosis and relevant advances.
format Online
Article
Text
id pubmed-8176700
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81767002021-06-04 Functional cure for chronic hepatitis B: accessibility, durability, and prognosis Song, Aixin Lin, Xiao Chen, Xinyue Virol J Review Hepatitis B surface antigen (HBsAg) clearance is regarded as the ideal endpoint for antiviral treatment in terms of drug withdrawal safety and improvements in prognosis. However, the overall rate of HBsAg clearance is low and differs based on treatment method and course. The recent application of combined and extended treatment strategies have improved the HBsAg clearance rate, and several patients achieved HBsAg clearance in clinical treatment. In addition, the durability of and clinical outcomes after HBsAg clearance have become the focus of both researchers and clinicians. This article reviews HBsAg clearance in terms of accessibility, durability, improvements in prognosis and relevant advances. BioMed Central 2021-06-03 /pmc/articles/PMC8176700/ /pubmed/34082765 http://dx.doi.org/10.1186/s12985-021-01589-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Song, Aixin
Lin, Xiao
Chen, Xinyue
Functional cure for chronic hepatitis B: accessibility, durability, and prognosis
title Functional cure for chronic hepatitis B: accessibility, durability, and prognosis
title_full Functional cure for chronic hepatitis B: accessibility, durability, and prognosis
title_fullStr Functional cure for chronic hepatitis B: accessibility, durability, and prognosis
title_full_unstemmed Functional cure for chronic hepatitis B: accessibility, durability, and prognosis
title_short Functional cure for chronic hepatitis B: accessibility, durability, and prognosis
title_sort functional cure for chronic hepatitis b: accessibility, durability, and prognosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176700/
https://www.ncbi.nlm.nih.gov/pubmed/34082765
http://dx.doi.org/10.1186/s12985-021-01589-x
work_keys_str_mv AT songaixin functionalcureforchronichepatitisbaccessibilitydurabilityandprognosis
AT linxiao functionalcureforchronichepatitisbaccessibilitydurabilityandprognosis
AT chenxinyue functionalcureforchronichepatitisbaccessibilitydurabilityandprognosis

Ejemplares similares